{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T08:00:23Z","timestamp":1764403223062,"version":"3.37.3"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Introduction<\/jats:title>\n<jats:p>Glecaprevir\/pibrentasvir (G\/P) has demonstrated high rates (&gt;95%) of sustained virologic response at posttreatment Week 12 (SVR12) in treatment-na\u00efve (TN) patients with hepatitis C virus (HCV) infection and compensated cirrhosis (CC). Here, in a key real-world subset of TN Italian patients with CC, we evaluated the effectiveness and safety of 8-week G\/P treatment, including subgroups of interest such as those with genotype 3 (GT3) infection, elderly patients, and those with more advanced liver disease.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Subanalysis of Italian patients enrolled in the CREST study. The full analysis set (FAS) included all patients enrolled in the study; the modified analysis set (MAS) excluded patients who discontinued G\/P for nonvirologic failure or who had missing SVR12 results. Primary and secondary endpoints included SVR12 and safety, respectively.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Of 42 patients included in the FAS, 1 discontinued for unknown reasons, and 2 had missing SVR12 data, leaving 39 patients included in the MAS. At treatment initiation, 74% of patients had \u22651 comorbidity, and 62% were receiving concomitant medications, including some that may potentially interact with G\/P. SVR12 was achieved in 100% of patients in the MAS, and in 95% in the FAS. In subgroups of interest, the proportion of patients achieving SVR12 in the MAS (and FAS) was: 100% (94%) for patients \u226565 years, 100% (86%) for GT3, and 100% (100%) for patients with platelet count &lt;150 \u00d7 10<jats:sup>9<\/jats:sup>\/L and FibroScan<jats:sup>\u00ae<\/jats:sup> &gt;20 kPa. Overall, 2 (5%) patients had an adverse event and neither were serious.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Results from this real-world Italian cohort demonstrated the safety and effectiveness of 8-week G\/P, with SVR12 rate &gt;95%, even in elderly patients. These findings further support real-world evidence of the use of short-course G\/P treatment in all patients with CC, including those with GT3, and those with advanced liver disease.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0280165","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T18:32:41Z","timestamp":1675362761000},"page":"e0280165","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety and effectiveness of 8 weeks of Glecaprevir\/Pibrentasvir in challenging HCV patients: Italian data from the CREST study"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0941-3226","authenticated-orcid":true,"given":"Alessio","family":"Aghemo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcello","family":"Persico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"D\u2019Ambrosio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Andreoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Villa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhi","family":"Bhagat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Gallinaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliana","family":"Gualberti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rocco Cosimo Damiano","family":"Merolla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Gasbarrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2023,2,2]]},"reference":[{"issue":"5","key":"pone.0280165.ref001","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: Final update of the series","volume":"73","author":"European Association for the Study of the Liver, Clinical Practice Guidelines Panel Chair, EASL Governing Board representative, Panel members","year":"2020","journal-title":"J Hepatol"},{"key":"pone.0280165.ref002","unstructured":"World Health Organization (WHO). Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016\u20132021: actions for impact. 2021 [June 2022]. https:\/\/www.who.int\/publications\/i\/item\/9789240027077."},{"key":"pone.0280165.ref003","doi-asserted-by":"crossref","first-page":"100442","DOI":"10.1016\/j.epidem.2021.100442","article-title":"Estimated prevalence of undiagnosed HCV infected individuals in Italy: A mathematical model by route of transmission and fibrosis progression","volume":"34","author":"LA Kondili","year":"2021","journal-title":"Epidemics"},{"issue":"1","key":"pone.0280165.ref004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-022-07042-w","article-title":"A mathematical model by route of transmission and fibrosis progression to estimate undiagnosed individuals with HCV in different Italian regions","volume":"22","author":"LA Kondili","year":"2022","journal-title":"BMC Infect Dis"},{"key":"pone.0280165.ref005","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2147\/CEOR.S136456","article-title":"Epidemiology, patient profile, and health care resource use for hepatitis C in Italy","volume":"9","author":"D Sangiorgi","year":"2017","journal-title":"Clinicoecon Outcomes Res"},{"issue":"4","key":"pone.0280165.ref006","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.idc.2017.07.014","article-title":"Hepatitis C virus infection in the older patient","volume":"31","author":"M Reid","year":"2017","journal-title":"Infect Dis Clin"},{"key":"pone.0280165.ref007","unstructured":"World Health Organization (WHO). Hepatitis C Fact Sheet [Internet]. 2021 [October 04, 2021]. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c."},{"issue":"5","key":"pone.0280165.ref008","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/liv.15216","article-title":"Implementation of HCV screening in the 1969\u20131989 birth\u2010cohort undergoing COVID\u201019 vaccination","volume":"42","author":"R D\u2019Ambrosio","year":"2022","journal-title":"Liver International"},{"key":"pone.0280165.ref009","article-title":"HCV point of care screening in people tested for SARS\u2010CoV\u20102 in a social\u2010housing neighbourhood of Milan, Italy","author":"M Beltrami","year":"2022","journal-title":"Liver International"},{"journal-title":"Liver International","article-title":"Screening for hepatitis C at the time of the pandemic: Need to adjust the shot","author":"P Torre","key":"pone.0280165.ref010"},{"key":"pone.0280165.ref011","article-title":"Hepatitis C screening during SARS\u2010CoV\u20102 testing or vaccination. Experience in an area of southern Italy in the province of Salerno","author":"P Torre","year":"2022","journal-title":"Liver International"},{"key":"pone.0280165.ref012","doi-asserted-by":"crossref","unstructured":"Vigan\u00f2 M, Cerini F, Ridolfo S, Rumi MG. HCV screening in the 1969\u20131989 birth-cohort: is not enough! Liver International: Official Journal of the International Association for the Study of the Liver. 2022.","DOI":"10.1111\/liv.15316"},{"key":"pone.0280165.ref013","unstructured":"AbbVie. Maviret EU Summary of Product Characteristics [Internet]. 2021 [October 04, 2021]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/maviret-epar-product-information_en.pdf."},{"key":"pone.0280165.ref014","unstructured":"AbbVie. Mavyret US Package Insert [Internet]. 2021 [October 04, 2021]. https:\/\/www.rxabbvie.com\/pdf\/mavyret_pi.pdf."},{"issue":"4","key":"pone.0280165.ref015","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa1702417","article-title":"Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection","volume":"378","author":"S Zeuzem","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"pone.0280165.ref016","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jhep.2019.10.020","article-title":"Glecaprevir\/pibrentasvir for 8 weeks in treatment-naive patients with chronic HCV genotypes 1\u20136 and compensated cirrhosis: The EXPEDITION-8 trial","volume":"72","author":"RS Brown","year":"2020","journal-title":"J Hepatol"},{"issue":"3","key":"pone.0280165.ref017","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cgh.2017.09.027","article-title":"Efficacy of glecaprevir\/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis","volume":"16","author":"T Asselah","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"pone.0280165.ref018","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/ggi.13919","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in patients with hepatitis C virus infection aged \u226575 years","volume":"20","author":"A Kinoshita","year":"2020","journal-title":"Geriatr Gerontol Int"},{"issue":"6","key":"pone.0280165.ref019","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jhep.2020.01.025","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis","volume":"72","author":"P Lampertico","year":"2020","journal-title":"J Hepatol"},{"issue":"5","key":"pone.0280165.ref020","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1007\/s12325-020-01301-5","article-title":"Effectiveness of 8-week glecaprevir\/pibrentasvir for treatment-naive, compensated cirrhotic patients with chronic hepatitis C infection","volume":"37","author":"SL Flamm","year":"2020","journal-title":"Adv Ther"},{"issue":"7","key":"pone.0280165.ref021","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1111\/liv.14937","article-title":"Glecaprevir\/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis C-Registry","volume":"41","author":"H Klinker","year":"2021","journal-title":"Liver Int"},{"key":"pone.0280165.ref022","first-page":"954A","article-title":"Addressing barriers to hepatitis C virus (HCV) elimination: real-world outcomes in historically underserved patients with chronic HCV infection treated with glecaprevir\/pibrentasvir","volume":"70","author":"P Lampertico","year":"2019","journal-title":"Hepatology"},{"key":"pone.0280165.ref023","article-title":"Real-world outcomes in historically underserved patients with chronic hepatitis C infection treated with glecaprevir\/pibrentasvir","author":"A Aghemo","year":"2021","journal-title":"Infect Dis Ther"},{"issue":"3","key":"pone.0280165.ref024","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jhep.2018.11.011","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir in 723 patients with chronic hepatitis C","volume":"70","author":"R D\u2019Ambrosio","year":"2019","journal-title":"J Hepatol"},{"issue":"9","key":"pone.0280165.ref025","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1007\/s12325-020-01449-0","article-title":"Real-world clinical practice use of 8-week glecaprevir\/pibrentasvir in treatment-na\u00efve patients with compensated cirrhosis","volume":"37","author":"P Lampertico","year":"2020","journal-title":"Adv Ther"},{"issue":"10","key":"pone.0280165.ref026","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1111\/liv.14170","article-title":"Real\u2010life glecaprevir\/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study","volume":"39","author":"M Persico","year":"2019","journal-title":"Liver International"},{"key":"pone.0280165.ref027","first-page":"1","article-title":"Safety and effectiveness using 8 weeks of glecaprevir\/pibrentasvir in HCV-infected treatment-na\u00efve patients with compensated cirrhosis: the CREST Study","author":"M Cornberg","year":"2022","journal-title":"Adv Ther"},{"issue":"4","key":"pone.0280165.ref028","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"C Clopper","year":"1934","journal-title":"Biometrika"},{"key":"pone.0280165.ref029","unstructured":"Liverpool Uo. Hep drug interactions. https:\/\/www.hep-druginteractions.org\/checker. Published 2019. [June 2022]."},{"issue":"2","key":"pone.0280165.ref030","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s40121-021-00410-0","article-title":"Addressing HCV elimination barriers in Italy: healthcare resource utilization and cost impact using 8 weeks\u2019 glecaprevir\/pibrentasvir therapy","volume":"10","author":"M Andreoni","year":"2021","journal-title":"Infect Dis Ther"},{"issue":"3","key":"pone.0280165.ref031","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"S Blach","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"pone.0280165.ref032","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s40121-022-00599-8","article-title":"Efficacy and safety of 8-or 12 weeks of glecaprevir\/pibrentasvir in patients with evidence of portal hypertension","volume":"11","author":"RS Brown","year":"2022","journal-title":"Infect Dis Ther"},{"issue":"1","key":"pone.0280165.ref033","doi-asserted-by":"crossref","first-page":"e0208506","DOI":"10.1371\/journal.pone.0208506","article-title":"Safety and efficacy of glecaprevir\/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older","volume":"14","author":"GR Foster","year":"2019","journal-title":"PLoS One"},{"issue":"Supplement_5","key":"pone.0280165.ref034","doi-asserted-by":"crossref","first-page":"S286","DOI":"10.1086\/427442","article-title":"Addressing tri-morbidity (hepatitis C, psychiatric disorders, and substance use): the importance of routine mental health screening as a component of a comanagement model of care","volume":"40","author":"M Fireman","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"1","key":"pone.0280165.ref035","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/liv.14283","article-title":"Direct-acting antiviral interactions with opioids, alcohol or illicit drugs of abuse in HCV-infected patients","volume":"40","author":"K Ing Lorenzini","year":"2020","journal-title":"Liver Int"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0280165","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T18:33:09Z","timestamp":1675362789000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0280165"}},"subtitle":[],"editor":[{"given":"Umberto","family":"Vespasiani-Gentilucci","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,2,2]]},"references-count":35,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0280165","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2023,2,2]]}}}